Explore the Global Generalized Myasthenia Gravis (GMG) Managements Market — Key Trends, Regional Growth, Top Players, and 10-Year Forecast from 2026 to 2036

Future Market Insights

Generalized Myasthenia Gravis (GMG) Managements Market

Key Insight

Generalized myasthenia gravis (GMG) management sales will grow through 2036, led by monoclonal antibodies at 36.9% of the drug types segment in 2026. The market was valued at USD 1.53 billion in 2025 and is expected to reach USD 3.2 billion by 2036, creating an incremental opportunity of USD 1.61 billion.

April 28, 2026

Anurag Sharma

296 Pages

Cite this Report

Generalized Myasthenia Gravis (GMG) Managements Market

https://www.futuremarketinsights.com/reports/generalized-myasthenia-gravis-managements-market

License

Buy Now

Summary ToC Companies

Key Players

Alexion Pharmaceuticals Inc
Argenx SE
Argenx SE all
CSL Behring
Grifols S.A
Kezar Life Sciences
Novartis
Roche
Takeda Pharmaceuticals
UCB S.A

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Generalized Myasthenia Gravis (GMG) Managements Market

Key Players

Similar Industry Reports